Skip to content

Journal of Psychoactive Drugs

ISSN 0279-1072, 2159-9777

415 papers in the library · 13,118 citations · publishing 1976-2026

Papers

Sort Most recent Most cited

A Clinical Plan for MDMA (Ecstasy) in the Treatment of Posttraumatic Stress Disorder (PTSD): Partnering with the FDA

Journal of Psychoactive Drugs June 1, 2002 Rick Doblin 98 citations

The FDA and the Spanish Ministry of Health have concluded that the risk/benefit ratio is favorable under certain circumstances for clinical studies investigating MDMA-assisted psychotherapy. Both agencies have approved pilot studies in chronic posttraumatic stress disorder (PTSD) patients who have failed to obtain relief from at least one course of conventional treatment. These studies, the...

DOI: 10.1080/02791072.2002.10399952 (opens in new tab) MDMA Ecstasy Posttraumatic stress Multidisciplinary approach +2

Acute Psychological and Neurophysiological Effects of MDMA in Humans

Journal of Psychoactive Drugs June 1, 2002 Franz X. Vollenweider, Matthias E. Liechti, Alex Gamma et al. 92 citations

Since the mid 1990s, MDMA has been increasingly used as a recreational drug called "Ecstasy" by young people in Europe and the United States. However, despite the widespread recreational use of Ecstasy, systematic data on the psychological and neurobiological effects of MDMA have been scant. To further our understanding of the mechanism of action of MDMA, the authors conducted several studies...

MDMA: A Review of Epidemiological Data

Journal of Psychoactive Drugs June 1, 2002 Mim J. Landry 87 citations

This article reviews recent surveys and reports that provide insight regarding prevalence, frequency, trends, perceptions, and seizures of methylenedioxymethamphetamine (MDMA) or "Ecstasy." An estimated 6.4 million individuals have used MDMA. Among students in the eighth, 10th, and 12th grades, MDMA use has substantially increased from mid-1990 levels to 2001, with sharp increases noted in 2000...

Negative Experiences on Ecstasy: The Role of Drug, Set, and Setting

Journal of Psychoactive Drugs June 1, 2002 Karen Mcelrath, Kieran McEvoy 56 citations

Similar to other sociological studies of Ecstasy use, the authors' research suggests that Ecstasy users tend to report positive effects of the drug. However, we also observed that most users experienced at least one adverse psychological outcome while using Ecstasy. The present study examines those negative experiences within the context of drug, set and setting. Data were collected through...

Hallucinogens and redemption.

Journal of Psychoactive Drugs 2002 Marlene Dobkin De Rios, Charles S. Grob, John R. Baker 58 citations

This article examines drug substitution with regard to hallucinogens (ayahuasca, ibogaine, peyote and LSD) set within the concept of redemption. The model examines both religious and secular approaches to the contemporary use of hallucinogens in drug substitution, both by scientists and in religious settings worldwide. The redemptive model posits that the proper use of one psychoactive...

Snuff synergy: preparation, use and pharmacology of yopo and Banisteriopsis caapi among the Piaroa of southern Venezuela.

Journal of Psychoactive Drugs 2002 Robin Rodd 30 citations

Current understanding of the preparation and use of yopo, a hallucinogenic snuff made from the ground seeds of the Anadenanthera peregrina tree, has departed little from the accounts of scientists and travelers made over a century ago. Schultes and others have made refinements to these early accounts. While several scholars have drawn attention to the fact that little ethnographic work has been...

Ecstasy: America's new "reefer madness".

Journal of Psychoactive Drugs 2002 Marsha Rosenbaum

MDMA (3,4-methylenedioxymethamphetamine) was first used as a legal adjunct to psychotherapy in the 1970s. By the early 1980s, "Ecstasy" had become a tiny part of the recreational American drug scene, and was ultimately criminalized in 1986. For a decade use continued, but remained quiet. By the end of the 1990s, increased supply, demand, seizures of pills, arrests of distributors associated...

MDMA misrepresentation: an unresolved problem for Ecstasy users.

Journal of Psychoactive Drugs 2002 Gregory N Hayner

The demand for MDMA (methylenedioxymethamphetamine) has increased, especially among teenagers 12 to 18 years old. It is estimated that approximately 2.8 million teens have at least tried this drug. Coincident with this trend has been an increasing body of literature that questions the safety of MDMA consumption in terms of possibly permanent neurological damage, associated with behavioral and...

Preventing problems in Ecstasy users: reduce use to reduce harm.

Journal of Psychoactive Drugs 2002 Matthew J. Baggott

Increasing use of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") has been accompanied by concern about acute and possible long-term toxicity. This article discusses acute serious toxicity, chronic toxicity, and common problems associated with Ecstasy use, as well as the implications of these areas for prevention programs targeted at current Ecstasy users. The low incidence of serious...

An Exploration of the History and Controversies Surrounding MDMA and MDA

Journal of Psychoactive Drugs September 1, 2001 Alana Rae. Pentney 94 citations

In existence for nearly a century, 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") have gained quite a reputation. Perceived by some as dangerous neurotoxins, and by others as potential psychotherapeutics, these compounds have become a center of controversy among academics and law enforcement officials, and in the process have gained extensive media...

Pharmepéna-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine.

Journal of Psychoactive Drugs 2001 J Ott 106 citations

Summarized are psychonautic bioassays (human self-experiments) of pharmepéna--crystalline 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT; O-Me-bufotenine), at times combined with crystalline beta-carbolines (harmaline or harmine). These substances were administered via intranasal, sublingual and oral routes, by way of pharmacological modeling of diverse South American shamanic inebriants...

DOI: 10.1080/02791072.2001.10399925 (opens in new tab) Full text (opens in new tab) Psychedelics: 5-MEO-DMT Beta-carbolines Psychoactive compounds Hallucinogens +21

Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine.

Journal of Psychoactive Drugs 2001 J Ott 60 citations

Summarized are psychonautic bioassays (human self-experiments) of pharmañopo--crystalline bufotenine (5-HO-DMT; 5-hydroxy-N,N-dimethyltryptamine; dimethylserotonine), at times combined with harmaline or harmine-via intranasal, sublingual, intrarectal, pulmonary (inhaled vapor) and oral routes. This is done by way of pharmacological modeling of diverse South American shamanic inebriants,...

DOI: 10.1080/02791072.2001.10400574 (opens in new tab) Full text (opens in new tab) Traditional shamanism Ancient mixtures Traditional practices Bufotenine +11

An "accidental" acute psychosis with ecstasy use.

Journal of Psychoactive Drugs 2001 G Vaiva, V Boss, D Bailly et al.

Over the last 10 years, Europe has witnessed the development of the ecstasy phenomenon; this term is used to describe several products sharing more or less the same effects. The most widely used and hence the most well known is 3,4 MDMA, but MDA, MDEA, MBDB and even 2CB or nexus are available. The psychopathological consequences of MDMA use in man are relatively poorly understood. The case...

A case study of space-time distortion during a total lunar eclipse following street use of LSD.

Journal of Psychoactive Drugs 2001 K A Dawson

Although psychedelics can induce "cosmic" consciousness through severe distortions of time and space perceptions, little attention has been given to examination of this psychopharmacological property. With the hope of providing an impetus to further research in this area, a case of cosmic perception under the influence of LSD is reported which included the apparent movement of consciousness to...

The nonmedical use of ketamine, part two: A review of problem use and dependence.

Journal of Psychoactive Drugs 2001 K L Jansen, R Darracot-Cankovic

This is the second part of a review of the nonmedical use of ketamine. Part one discussed the history of ketamine, the sought-after effects for which it is taken in a nonmedical context, how these are produced, common adverse effects, the ketamine schizophrenia model and the neurotoxicity issue. Part two reviews what is currently known about problem use of ketamine, ketamine dependence,...

A Review of the Nonmedical Use of Ketamine: Use, Users and Consequences

Journal of Psychoactive Drugs December 1, 2000 Karl Jansen 229 citations

Ketamine is a dissociative anesthetic with an accepted place in human medicine. Ketamine also has psychedelic properties, and there has been a recent increase in nonmedical use linked with the growth of the "dance culture." This has attracted little comment in the formal literature but has been the subject of many reports in the media. Myths and misunderstandings are common. The psychedelic...

Bufotenine: toward an understanding of possible psychoactive mechanisms.

Journal of Psychoactive Drugs 2000 M C Mcbride 71 citations

A review of the neuropharmacology of the alleged hallucinogen bufotenine is presented, including recent experimental results showing activity similar to LSD and other known hallucinogens (psilocin and 5-MeO-DMT) at the purported hallucinogenic serotonin (5-HT) receptors, 5-HT2A and 5-HT2C. In addition, current reports of computer modeling of the receptors and ligand binding sites give evidence...

Pharmahuasca: Human Pharmacology of Oral DMT Plus Harmine

Journal of Psychoactive Drugs April 1, 1999 Jonathan Ott 136 citations

A summary is presented of human self-experiments or psychonautic bioassays of pharmahuasca--capsules containing crystalline N,N-dimethyltryptamine (DMT) plus harmine, as well as combinations of other psychoactive tryptamines with other beta-carbolines. The 1967 Holmstedt-Lindgren hypothesis of the ayahuasca effect--oral psychoactivity of DMT consequent to monoamine-oxidase (MAO) inhibition from...

The Duboisia genus, Australian aborigines and suggestibility.

Journal of Psychoactive Drugs 1999 M D De Rios, R Stachalek 14 citations

Plant hallucinogens, such as those of the Duboisia genus called pituri, have been used by tribal elders in Australian aboriginal populations to create managed states of consciousness, to provide their youth with a fast-paced educational experience, and to inculcate values, beliefs and religious tenets. Use of the suggestible states created by such substances (particularly in pubertal initiatory...

Three cases of delirium after "ecstasy" ingestion.

Journal of Psychoactive Drugs 1999 A Alciati, B Scaramelli, A Fusi et al.

Three cases of delirium experienced by three young friends after recreational use of "ecstasy" are reported--a syndrome which, to the best of the authors' knowledge, has not been previously observed in MDMA abusers. Special attention is given to the etiological factors and clinical features of the adverse reaction.

A Method of Conducting Therapeutic Sessions with MDMA

Journal of Psychoactive Drugs December 1, 1998 George Greer, Requa Tolbert 187 citations

A method for preparing clients and conducting therapeutic sessions with 3,4-methylenedioxymethamphetamine (MDMA) is described, with emphasis on the need for careful attention to the mental set of therapists and clients and the setting of the session. The therapists' belief was that MDMA inhibited the fear response to a perceived emotional threat, allowing the client to place the emotional...

Hallucinogenic Drugs and Plants in Psychotherapy and Shamanism

Journal of Psychoactive Drugs December 1, 1998 Ralph Metzner 140 citations

Western psychotherapy and indigenous shamanic healing systems have both used psychoactive drugs or plants for healing and obtaining knowledge (called "diagnosis" or "divination" respectively). While there are superficial similarities between psychedelic-assisted psychotherapy and shamanic healing with hallucinogenic plants, there are profound differences in the underlying worldview and...

Ayahuasca Preparations and Serotonin Reuptake Inhibitors: A Potential Combination for Severe Adverse Interactions

Journal of Psychoactive Drugs December 1, 1998 James C. Callaway, Charles S. Grob 134 citations

The Amazonian psychoactive plant beverage ayahuasca has attracted increasing interest in recent years. Little attention has been given, however, to potentially dangerous interactions with other drugs. In particular, the interaction between the potent monoamine oxidase-inhibiting harmala alkaloids in ayahuasca and the selective serotonin reuptake inhibitor (SSRI) class of antidepressants may...

DOI: 10.1080/02791072.1998.10399712 (opens in new tab) Ayahuasca Hallucinogen Pharmacology Reuptake inhibitor +3

Dr. Leary's Concord Prison Experiment: A 34-Year Follow-up Study

Journal of Psychoactive Drugs December 1, 1998 R Doblin 29 citations

This study is a long-term follow-up to the Concord Prison Experiment, one of the best-known studies in the psychedelic psychotherapy literature. The Concord Prison Experiment was conducted from 1961 to 1963 by a team of researchers at Harvard University under the direction of Timothy Leary. The original study involved the administration of psilocybin-assisted group psychotherapy to 32 prisoners...

DOI: 10.1080/02791072.1998.10399715 (opens in new tab) Psychedelic therapy Psilocybin treatment Hallucinogen therapy Psychedelic medicine +15